Background: Atopic dermatitis (AD) and psoriasis are the 2 most common chronic inflammatory skin diseases. There is an unmet medical need to overcome limitations for transcutaneous drug development posed by the skin barrier. Objective: We aimed to identify a novel transdermal delivery peptide and to develop a transcutaneously applicable immunomodulatory protein for treating AD and psoriasis. Methods: We identified and generated reporter proteins conjugated to astrotactin 1-derived peptide (AP), a novel transdermal delivery peptide of human origin, and analyzed the intracellular delivery efficiency of these proteins in mouse and human skin cells and tissues using multiphoton confocal microscopy. We also generated a recombinant therapeutic protein, AP-recombinant protein tyrosine phosphatase (rPTP), consisting of the phosphatase domain of the T-cell protein tyrosine phosphatase conjugated to AP. The immunomodulatory function of AP-rPTP was confirmed in splenocytes on cytokine stimulation and T-cell receptor stimulation. Finally, we confirmed the in vivo efficacy of APrPTP transdermal delivery in patients with oxazolone-induced contact hypersensitivity, ovalbumin-induced AD-like, and imiquimod-induced psoriasis-like skin inflammation models. Results: AP-conjugated reporter proteins exhibited significant intracellular transduction efficacy in keratinocytes, fibroblasts, and immune cells. In addition, transcutaneous administration of AP-dTomato resulted in significant localization into the dermis and epidermis in both mouse and human skin. AP-rPTP inhibited phosphorylated signal transducer and activator of transcription (STAT) 1, STAT3, and STAT6 in splenocytes and also regulated T-cell activation and proliferation. Transcutaneous administration of AP-rPTP through the paperpatch technique significantly ameliorated skin tissue thickening, inflammation, and cytokine expression in both AD-like and psoriasis-like dermatitis models. Conclusion: We identified a 9-amino-acid novel transdermal delivery peptide, AP, and demonstrated its feasibility for transcutaneous biologic drug development. Moreover, AP-rPTP is a novel immunomodulatory drug candidate for human dermatitis. (J Allergy Clin Immunol 2018;141:137-51.) 
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Key words: Atopic dermatitis, psoriasis, transdermal delivery peptide, protein tyrosine phosphatase, T-cell protein tyrosine phosphatase, transcutaneous drug, immunomodulatory protein Atopic dermatitis (AD) and psoriasis are among the most common chronic and relapsing cutaneous inflammatory diseases. 1 AD affects up to 25% of all children worldwide and 10% of all adults in the United States. 2, 3 Psoriasis affects about 3.2% of the population worldwide, including 7.2 million adults in the United States, and is estimated to affect 2% to 4% of the population of Western countries. 4 These inflammatory skin diseases are also often related to mental health problems, such as depression and suicidal ideation. 5 Moreover, the skin barrier makes drug delivery highly inefficient, resulting in a major unmet medical need for effective AD and psoriasis treatments. [6] [7] [8] [9] [10] Both diseases involve fundamental barrier dysfunction, keratinocyte hyperproliferation, increased transepidermal water loss (TEWL), and immune cell activation and infiltration. [11] [12] [13] T H 2 cells are predominant in the acute skin lesions of patients with AD. As the disease progresses, IL-12 secreted from infiltrated inflammatory dendritic epidermal cells, macrophages, and eosinophils causes T H 1 cells to become the predominant cell type. 1, 14 In patients with psoriasis, T H 1, T H 17, and gd T cells predominate. 12, 15 Recently, T H 17 and T H 22 lymphocyte subtypes were suggested to be involved in both AD and psoriasis. 16, 17 Because the pathology of AD and psoriasis is mainly propagated by various inflammatory cytokine responses, modulation of cytokine signaling, effector T-cell function, or both is believed to be the most promising strategy for AD and psoriasis drug development. 13, 18 Transdermal drug delivery has many advantages in treating inflammatory skin diseases, including convenience for patients and easy dose control. 9, 10, 19 Despite extensive studies regarding transdermal drug delivery, only a few drug formulations are commercially available. 10, 20 Many transdermal drug delivery systems (TDDSs) have been studied, including chemical penetration enhancers (CPEs), 8 microneedles, 21, 22 iontophoresis, 23 electroporation, 24 liposomes, 25 and nanoparticles. 26 The general utility of previous approaches is limited by their large molecular size or other inconvenient aspects, and many cause irritation or skin damage. 19, 27 Noninvasive and self-administered methods, such as skin-penetrating peptides (SPPs), have emerged as potential solutions, 10, 27 and classical cell-penetrating peptides (CPPs) and SPPs have also been studied for possible use in transdermal drug applications. TAT, 28 oligoarginines including R7 29 and R9
30
; PEP-1 31 ; TD-1 32 ; SPACE 33 ; and magainin, 34 are promising vehicles for delivering small molecules and macromolecules such as small interfering RNA (siRNA) and proteins into the skin tissue. However, no US Food and Drug Administration (FDA)-approved drugs using CPPs or SPPs are currently available for macromolecular delivery, suggesting reduced efficiency in human subjects or unexpected side effects or toxicities in clinical trials. 35 In this study we identified a novel superior transdermal delivery peptide, astrotactin 1-derived peptide (AP), which is derived from a human neuronal adhesion protein (astrotactin 1). In addition, we generated a novel immunomodulatory recombinant protein by conjugating AP to the phosphatase domain of T-cell protein tyrosine phosphatase (TC-PTP; ie, AP-rPTP). We showed that AP successfully delivered a protein into both mouse and human dermis and epidermis. Moreover, transcutaneous 
METHODS
For a complete description of the methods used in the in vitro and in vivo experiments, please see the Methods section in this article's Online Repository for this article at www.jacionline.org.
Purification of recombinant proteins
The purification protocol was modified from a previous method. 36 For further details, see the Methods section in this article's Online Repository.
Mice
C57BL/6 and BALB/c mice were purchased from Orient Bio (Daejeon, Korea). The mice were housed and bred in specific pathogen-free animal facilities at Hanyang University, the Korea Advanced Institute of Science and Technology, and Yonsei University. All mouse experimental procedures used in this study were approved by the Animal Care and Use Committees of Hanyang University, the Korea Advanced Institute of Science and Technology, and Yonsei University.
Human skin tissue
Normal human skin samples, with all identifiers removed, were obtained from the tissue procurement service of the Yale Department of Pathology; the Yale Human Investigations Committee declared that the use of this material was not considered human subject research.
Statistics
Data were analyzed by using 2-tailed Student t tests, 1-way ANOVA, or 2-way ANOVA by with GraphPad Prism software (version 6.0; GraphPad Software, San Diego, Calif). P values of less than .05 were considered significant.
RESULTS

Identification of AP, a novel skin CPP
With the aim of identifying novel skin CPPs, we performed a similarity search for peptides with multiple arginine or lysine amino acids, including TAT and R9, using the ScanProsite tool (http://prosite.expasy.org/scanprosite/) in the UniProtKB human database. We then filtered the results for candidates shorter than 10 amino acids. A strong candidate sequence was located in astrotactin 1, a neuronal adhesion protein. The candidate 9-amino-acid section of AP (amino acids 177-185) is highly conserved among various species (Fig 1, A) . We constructed plasmids expressing enhanced green fluorescent proteins (EGFPs) with or without AP, other control peptides were constructed, and each protein was purified, as previously descried. 36 Protein purity was confirmed by means of SDS-PAGE (Fig 1, B) . The purified EGFP recombinant proteins maintained their natural optical properties after peptide conjugation (see Fig E1 in this article's Online Repository for this article at www.jacionline.org).
Proteins were added to the culture medium of human keratinocyte cell lines (HaCaT cells) at various concentrations and for different lengths of time to analyze the skin cellpenetrating capability of the purified proteins in vitro. Flow cytometric analysis demonstrated that the addition of increasing concentrations of AP-EGFP to the medium resulted in a dramatic increase in intracellular fluorescence (Fig 1, C) . The maximal level of intracellular protein was observed at 1 hour and gradually decreased until 8 hours (Fig 1, D) . In keratinocytes and fibroblasts (NIH3T3), AP exhibited significantly more efficient intracellular protein delivery than TAT-EGFP and R9-EGFP, which are the most commonly used CPPs (Fig 1, E , and see Fig E2 in this article's Online Repository for this article at www.jacionline.org). AP-EGFP exhibited robust uptake into the cytoplasm and nuclei of both keratinocytes and fibroblasts, as observed by using both fluorescence and confocal microscopic analysis (Fig 1, F and  G) . The fluorescence signals of TAT-EGFP and R9-EGFP were also detected with longer exposure times (see Fig E3 in this article's Online Repository for this article at www.jacionline.org); however, their intensities were much lower than those of AP-EGFP.
Although skin cell delivery peptides have been identified by using CPPs or through Franz diffusion cells, their intracellular protein delivery efficiency is generally low in primary cells or tissues, 35 severely limiting the clinical applications of TDDSs. Primary epidermal cells from C57BL/6 mice were used to further evaluate the efficiency of intracellular AP delivery into skin cells. Mouse primary epidermal cells were isolated by using dispase and trypsin (Fig 1, H) , as previously described, 37 antigen-presenting cells) were analyzed separately, as shown in the gating strategy (Fig 1, I ). For each EGFP protein, 5 mmol/L was incubated with the isolated cells for 1 hour, after which intracellular fluorescence was analyzed by using flow cytometry. Significant intracellular fluorescence intensity of AP-EGFP was observed in all cellular populations, including CD45 2 keratinocytes, T cells, and antigen-presenting cells, such as Langerhans cells. In contrast, little internalization of control EGFP, TAT-EGFP, and R9-EGFP was observed (Fig 1, J , and see Fig E4 in this article's Online Repository for this article at www.jacionline.org). Collectively, these results suggest that AP is a novel and effective skin CPP with significantly more efficient intracellular protein delivery than conventional CPPs, such as TAT and R9.
Efficient transdermal protein delivery by AP into mouse and human skin tissue
Based on the potent protein delivery efficiency mediated by AP in keratinocytes and fibroblasts in vitro, we next determined its transdermal protein delivery efficiency in vivo. To enhance in vivo visualization, plasmids were constructed, and dTomato recombinant proteins fused to AP and other controls were generated (see Fig E5 in this article's Online Repository for this article at www.jacionline.org). Before transcutaneous protein application, the stratum corneum was removed from each mouse by using depilatory cream and tape stripping (see the Methods section for further details). On the dorsal skin of green fluorescent proteintransgenic mice, 100 mg of dTomato and AP-dTomato was applied for 6 hours through the paper-patch method. As shown in Fig 2, A, significant AP-dTomato fluorescence signal was observed in both the dermis and epidermis with overlapping green fluorescent protein-positive skin cells in the tissue, whereas the dTomato protein signal remained on the skin surface (Fig 2, A  and B ). In addition, the dermal fluorescence signal intensities of TAT-dTomato and R9-dTomato were much weaker than that of AP-dTomato (Fig 2, C) . (Fig 2, G) . H, Quantitative analysis of red fluorescence signals over the threshold in the dermis. I, Signals are represented as spheres (bar graph shows numbers of spheres). Quantitative analysis was performed with Imaris 8.2.0 software. Error bars indicate SDs. ***P < .001. n.s., Not significant.
For better visualization of AP-dTomato transdermal delivery, we performed multiphoton microscopic analysis in live mice. Proteins were administered by using the paper-patch technique for 6 hours, after which anesthetized mice were prepared under the microscope. Significant AP-dTomato fluorescence was observed at a skin depth of 40 to 120 mm, whereas R9-dTomato was predominantly present at a depth of 60 mm, and TATdTomato was mostly retained on the skin surface (Fig 2, D and E) . Z-projection data from 40 to 120 mm revealed accumulated fluorescence intensity in the sample tissue, suggesting that the total amount of dermis skin penetrated by dTomato was highest when conjugated to AP and was also greater than that of any of the other controls (Fig 2, F and G) . For quantitative analysis, significant fluorescence signals over the threshold were represented as spheres. The spheres were counted by using Imaris software (Bitplane, Zurich, Switzerland). This analysis revealed that significantly more protein was detected in the dermis of APdTomato treated mice than in that of other control mice (Fig 2,  H and I) .
Next, we determined the transdermal delivery efficiency of AP-dTomato protein in isolated human skin tissue. We applied 200 mg of protein through the paper-patch method onto isolated human breast skin tissue samples for 12 hours. For this incubation, the samples were placed on gauze and medium (Fig 3, A  and B) . The human breast skin tissue samples were procured as full-thickness specimens from healthy donors and exhibited much thicker epidermis and dermis than those of mouse skin tissue (Fig 3, C) . Using these human breast skin tissue samples from 3 different donors, we performed in vitro transcutaneous protein delivery experiments. Significant intracellular AP-dTomato signal was observed in both the dermis and epidermis of the human skin tissue samples, as indicated with a white arrow, based on colocalization with a nuclear stain. However, the signal of dTomato protein without any peptide conjugation was confined to the skin surface, and little intracellular signal of TAT-dTomato was observed (Fig  3, D) .
These results demonstrate that AP is an efficient skin tissuepenetrating peptide that enables transcutaneous protein delivery into the dermal and epidermal cells of both mouse and human skin.
Skin cell penetration mechanism of AP
The superior skin tissue penetration and intracellular delivery efficiency of AP-conjugated proteins prompted us to investigate the mechanisms by which the AP peptide mediates protein delivery. We hypothesized that the intracellular protein delivery mechanism to skin cells would mainly involve endocytosis, such as other conventional CPPs. To test this hypothesis, the intracellular fluorescence intensity of AP-EGFP in HaCaT cells was determined after incubation with various inhibitors, such as heparin, 38 methyl-b-cyclodextrin, 39 amiloride, 40 or chlorpromazine, 41 each of which could potentially interfere with the intracellular transduction of CPPs. The skin cell-penetrating efficiency of AP-EGFP was strongly inhibited by heparin (Fig 4, A) , methyl-bcyclodextrin (Fig 4, B) , and amiloride (Fig 4, C) but not by chlorpromazine (see Fig E6, A, in this article's Online Repository for this article at www.jacionline.org).
These results suggest that recombinant AP fusion proteins are internalized by lipid raft-mediated endocytosis, macropinocytosis, or both after heparan sulfate interaction. Conversely, the decreased internalization efficiency observed at low temperatures or in the presence of serum-containing medium (see Fig E6, B (Fig 4, A) , methyl-b-cyclodextrin (MbCD; Fig 4,  B) , or amiloride (Fig 4, C) . D, Arginine length optimization of the AP sequence. E, Characterization of the AP sequence in AP by amino acid mutation. F, Effect of cysteine modification on transduction efficacy. Error bars indicate SDs. **P < .01, ***P < .001, and ****P < .0001. MFI, Mean fluorescence intensity; n.s., not significant.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 and C) suggests that AP-EGFP is internalized by ATP-dependent and protein interaction-dependent mechanisms. These results suggest that the internalization mechanism of AP-EGFP consists predominantly of endocytosis initiated by heparan sulfate interaction, such as other CPPs.
Next, we investigated mutant versions of AP to determine the amino acids critical for its potent cell-penetrating capability. Because positively charged amino acids are key amino acids for interactions with proteoglycan, 42 we first generated argininedeleted versions of AP-EGFP, including AP(DR 1 )-EGFP (RRWCKRRR), AP(DR 9 )-EGFP (RRRWCKRR), and AP(DR 1 DR 9 )-EGFP (RRWCKRR), and determined their intracellular delivery efficiency in HaCaT cells (Fig 4, D) . A single arginine deletion at either the N-terminal or C-terminal end dramatically reduced intracellular protein delivery, suggesting that 3 arginine amino acids at both ends is the optimal number for protein transduction.
We next generated single mutants of the nonarginine amino acids in the AP sequence (W, C, and K). The cysteine mutant AP (APCA) showed the most dramatic decrease in transduction efficiency, whereas the tryptophan mutant (APWA) and lysine mutant (APKA) exhibited significantly reduced intracellular protein delivery (Fig 4, E) .
We also hypothesized that adding a cysteine residue to other CPPs, such as TAT, LPIN, and NP2, would increase their intracellular delivery efficiency. All CPPs with an additional cysteine residue appended to the C-terminal end of the sequence showed significantly increased in transduction efficiency in HaCaT cells (Fig 4, F) . Collectively, these results suggest that each amino acid in AP contributes to its potent skin cell-penetrating capability and that the composition of arginine, lysine, cysteine, and tryptophan is the optimal combination.
Recombinant TC-PTP conjugated to AP is a novel skin cell-penetrating immunomodulatory molecule Regulation of cytokine signaling is considered an ideal strategy for developing drugs intended to modulate the local inflammatory response in skin tissue. 18 TC-PTP (PTPN2) is an enzyme of the protein tyrosine phosphatase (PTP) family that is an attractive drug target for regulating the Janus kinase (JAK)-signal transducer and activator of transcription (STAT) cytokine receptor signaling pathway. This pathway includes JAK1, 43 45 and STAT6. 46 TC-PTP also inhibits T-cell receptor signaling molecules, such as Src family tyrosine kinases (Lck and Fyn). 47 We hypothesized that AP-conjugated TC-PTP would be an effective immunomodulator in patients with skin inflammatory diseases. To test this hypothesis, we generated DNA constructs (Fig 5, A) and used them to express and purify truncated versions of TC-PTP containing the catalytic domain and substrate binding site fused to the AP sequence (AP-rPTP) (Fig 5, B) . The 3-dimensional structure of AP-rPTP was predicted by using the structure modeling tools Sparks X and visualized with PyMOL. This analysis revealed that the recombinant fusion protein was expected to exhibit no significant changes compared with its original structure (Fig 5, C) . We further confirmed the phosphatase activity of purified recombinant AP-rPTP using a chromogenic substrate. This analysis revealed that the AP-rPTP exhibited significant enzymatic activity (Fig 5, D) .
We next confirmed the intracellular delivery efficiency of APrPTP into HaCaT cells. For these experiments, AP-rPTP was used at a concentration of 1 or 5 mmol/L, and cells were incubated with fusion protein for 1 hour. Flow cytometric analysis with an anti6xHis-tag antibody revealed that the fusion protein was significantly delivered into cells in a concentration-dependent manner (Fig 5, E) . The intracellular levels of AP-rPTP reached a maximum at 2 hours and then gradually decreased until 12 hours (Fig 5, F) .
We next determined whether AP-rPTP inhibits cytokine signaling in stimulated cells. To this end, mouse splenocytes were treated with AP-rPTP or AP-EGFP for 1 hour. The cells were then stimulated with IFN-g, IL-6, and IL-4 for 60, 15, and 30 minutes, respectively (Fig 5, G) . AP-rPTP significantly reduced STAT1, STAT3, and STAT6 phosphorylation, suggesting that AP-rPTP negatively regulates cytokine signaling in cells.
We next determined the regulatory effects of AP-rPTP on T cells by stimulating naive CD4 T cells sorted by means of fluorescence-activated cell sorting with anti-CD3 and anti-CD28 antibodies for 3 days, after which proliferating cells were analyzed by using the carboxyfluorescein succinimidyl ester assay. AP-rPTP treatment significantly reduced activated T-cell proliferation (Fig 5, H) . Moreover, the production of various cytokines (IL-2, IFN-g, IL-13, and IL-17) by mouse splenocytes activated with anti-CD3 and anti-CD28 antibodies was also significantly reduced by AP-rPTP (Fig 5, I) .
These results suggest that recombinant AP-rPTP is a potent regulatory molecule that inhibits both inflammatory cytokine signaling, T-cell activation, and T-cell proliferation.
Transdermal administration of AP-rPTP inhibits ADlike skin inflammation
To determine whether transdermal administration of AP-rPTP protein reduces skin inflammation, we used oxazolone (OXA)-induced contact hypersensitivity (CHS) and ovalbumin (OVA)-induced AD-like mouse models.
For the CHS model, mice were prepared for hair removal on day 0. On day 1, after initial sensitization with 2% OXA, 100 mg of protein was applied on each side of the ear through the paper-patch method every day for 6 days. The attached paper patches were firmly maintained by water surface tension for 1 hour on ears. Ear thickness was measured every day; on day 6, mice were challenged with 1% OXA, and skin tissue histology and cytokine mRNA analyses were performed 24 hours thereafter (Fig 6, A) . Ear thickness was significantly increased in the AP-EGFP-treated group; however, transcutaneous delivery of AP-rPTP by means of paper patch significantly inhibited ear thickening (Fig 6, B) , as demonstrated by the reduced weight of the ear skin biopsy samples (Fig 6, C) . Moreover, visual observation revealed that skin dryness was significantly improved in the AP-rPTP-treated tissue (Fig 6,  D) . Histologic hematoxylin and eosin staining of the skin tissue samples revealed significant cellular infiltration of neutrophils, eosinophils, and lymphocytes into the ear and marked epidermal hyperplasia in the AP-EGFP-treated group, whereas AP-rPTPtreated tissue exhibited significantly reduced pathologic signs (Fig 6, E , and see Fig E7 in this article's Online Repository for this article at www.jacionline.org). We observed similar results in a back skin CHS model (see Fig E8 in this article's Online Repository for this article at www.jacionline.org). Importantly, neither TAT-rPTP nor R9-rPTP inhibited this inflammatory response, suggesting that AP-mediated skin tissue penetration is critical for rPTP-mediated regulatory functions (see Fig E9 in this article' s Online Repository for this article at www.jacionline.org). In addition, the mRNA levels of the proinflammatory cytokines IL-1b and IL-6 (Fig 6, F) and the mRNA levels of the chemokines CXCL2 and CXCL5 (Fig 6,  G) were significantly reduced by AP-rPTP treatment. Cumulatively, these data suggest that AP-rPTP regulates OXAinduced CHS.
Next, we used an AD-like mouse model with the OVA antigen. To this end, 100 mg of OVA was applied to sterile gauze on the dorsal skin of BALB/c mice for 1 week, after which the protein was removed. This procedure was repeated 4 times at 2-week intervals. For the prevention group, 100 mg of AP-rPTP was coadministered with OVA during all 4 sensitizations. For the therapeutic group, AP-rPTP was coadministered with OVA only in the last 2 sensitizations (Fig 6, H) . Histologic analysis (hematoxylin and eosin staining) of inflammatory skin tissue from mice in the OVA plus PBS group revealed significant epidermal hyperplasia, edema, and substantial cellular infiltration; however, (Fig 5, E) and time-dependent (Fig 5, F) delivery of AP-rPTP into HaCaT cells. G, Dephosphorylation of STAT by AP-rPTP in mouse splenocytes. H, Inhibition of CD4 T-cell proliferation by AP-rPTP. CFSE, Carboxyfluorescein succinimidyl ester. I, Inhibition of cytokine production by AP-rPTP. Error bars indicate SDs. *P < .05, **P < .01, ***P < .001, and ****P < .0001. MFI, Mean fluorescence intensity. (Fig 6, F) and chemokine (Fig 6, G) (Fig 6, L) and eosinophils (Fig 6, M) . Values are expressed per field. N and O, Toluidine blue staining (Fig 6, N) and CD3 staining (Fig 6, O) of mast cells and CD3 T cells, respectively. P and Q, Quantification of infiltrated mast cells (Fig 6, P) and CD3 T cells (Fig 6, Q) . Values are expressed per field. R, Quantification of IL-13 cytokine mRNA expression levels in skin. S, TEWL measurements of back skin after the last OVA sensitization. Error bars indicate SEMs. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
transdermal delivery of AP-rPTP significantly reduced inflammatory symptoms and epidermal thickness in both the prevention and therapeutic groups (Fig 6, I-K) . Moreover, significantly fewer neutrophils and eosinophils had infiltrated in the AP-rPTPtreated group (Fig 6, L and M, and see Fig E10 in this article's Online Repository for this article at www.jacionline.org). Analysis of infiltrated mast cells and T cells, which were stained with toluidine blue and anti-CD3 antibodies, respectively (Fig 6, N and O) , revealed that mice in the AP-rPTP-treated groups exhibited fewer mast cells and T cells than mice in the control group (Fig 6, P  and Q) . In addition, IL-13 mRNA levels in skin tissue were significantly decreased in both the prevention and therapeutic groups, suggesting that T H 2 inflammation is reduced by the corresponding treatments (Fig 6, R) . After the last OVA sensitization, TEWL of the skin was also measured. This analysis revealed that TEWL was significantly decreased in the AP-rPTP-treated groups, suggesting that transdermal delivery of AP-rPTP improves skin epithelial cell function (Fig 6, S) .
These data collectively suggest that transcutaneous administration of AP-rPTP by using the paper-patch technique significantly inhibits CHS and AD-like skin inflammatory diseases.
Transdermal administration of AP-rPTP inhibits psoriasis-like skin inflammation
To determine whether AP-rPTP could regulate other types of inflammatory skin diseases, such as psoriasis, we examined the effects of AP-rPTP in an imiquimod-induced psoriasis-like (Fig 7, F) and antimicrobial peptide (Fig 7, G) mRNA expression levels in skin. H, Representative gross images of back skin 24 hours after the last imiquimod challenge. I, Scoring of skin thickening, scaling, and erythema. PASI, Psoriasis Area and Severity Index. J, Histologic analysis of back skin (scale bar 5 200 mm). K, Quantification of epidermal thickness. Error bars indicate SEMs. *P < .05, **P < .01, ***P < .001, and ****P < .0001.
J ALLERGY CLIN IMMUNOL VOLUME 141, NUMBER 1 dermatitis model. For this model, mice were prepared for hair removal on day 0. Specifically, 70 mg of AP-rPTP and the control protein was applied on each side of the ear for 1 hour by using the paper-patch technique. Next, a mixture of 20 mg of Aldara cream (5% imiquimod) and an additional 30 mg of protein was applied for 6 consecutive days, after which disease pathology was analyzed on day 7 (Fig 7, A) . The ear thickness of AP-EGFPtreated mice increased significantly from days 2 to 7 of imiquimod treatment, whereas transdermal AP-rPTP treatment significantly inhibited this ear thickening (Fig 7, B) , inflammatory cellular infiltration (Fig 7, C) , and epidermal hyperplasia (Fig 7, D) . Moreover, fewer infiltrated lymphocytes and neutrophils were observed in the AP-rPTP group (Fig 7, E) . mRNA expression levels of IL-17A, IL-17F, and IL-6 in ear skin tissue were dramatically reduced by AP-rPTP administration (Fig 7,  F) . Furthermore, significant reduction of S100A8/9 (Fig 7, G) , a mediator of neutrophil chemotaxis and the adhesion effect, was observed.
We also performed similar experiments on mouse back skin, which has thicker epidermis and dermis than ear skin. Transcutaneous treatment of back skin with AP-rPTP also significantly prevented imiquimod-induced dermatitis signs, such as skin thickening, scaling, and erythema (Fig 7, H and I) . Histologic analysis of the AP-rPTP-treated group revealed fewer infiltrated immune cells and elongated rete ridges (Fig 7, J) and reduced epidermal thickness (Fig 7, K) than in the AP-EGFP group.
These results collectively suggest that transdermal administration of AP-rPTP by using the paper-patch technique efficiently regulates psoriasis-like inflammatory skin disease.
DISCUSSION
In the present study we described a novel transdermal delivery peptide, AP, which was derived from human astrotactin 1. We showed that this peptide exhibits superior delivery efficiency in both mouse and human skin. In addition, conjugation of AP to the catalytic domain of T-cell protein tyrosine phosphatase (APrPTP) resulted in a protein with immunomodulatory functions in cytokine signaling and T-cell activation and proliferation. Finally, we demonstrated that AP-rPTP is a novel therapeutic protein that can be applied transcutaneously in patients with AD and psoriasis.
AD and psoriasis are very common inflammatory diseases.
3,4
The only available topical treatments for regulating inflammation are corticosteroids, which suppress various inflammatory pathways, 48 and tacrolimus and pimecrolimus, which target calcineurin binding to FK506-binding protein (FKBP12). 49 These small-molecule ointments are currently used as topical therapeutics, although they have various efficacy and safety limitations. 50 Patients with severe symptoms have also been treated with systemic immunosuppressants, such as cyclosporine or corticosteroids, 51 although a number of undesirable systemic side effects have been reported, including hypertension, nephrotoxicity, and gastritis. 51 Therefore there is a significant unmet need for the development of a safe and effective drug for AD and psoriasis. 6 The stratum corneum, which forms the outermost layer of the epidermis, hinders penetration of the skin barrier by macromolecules. 9 Because only small molecules (<500 Dalton) can penetrate the stratum corneum, cyclosporine (1202 Da) was not effective through transcutaneous administration for AD. 7, 52 With the aim of overcoming this size limitation, cyclosporine was fused to hepta-arginine (R7-CsA); transcutaneous administration of this peptide reduced ear inflammation in a CHS model. 30 This result implies that CPPs could potentially be used for transcutaneous drug delivery.
In 1979, the scopolamine patch (used for motion sickness) became the first FDA-approved transdermal drug. TDDSs have since been extensively developed, with 39 drugs approved as of 2014. 20 TDDSs are classified into 3 generations, as defined by Prausnitz et al. 10 First-generation topical formulations, such as patches, gels, and liquid sprays, comprise the majority of currently approved transdermal drugs on the market. This system is more attractive than oral delivery, but the drug candidates must be small, lipophilic, and efficacious at low doses. Secondgeneration systems, such as chemical enhancers (CPEs), 53 iontophoresis, 54 and noncavitational ultrasound, 55 increase skin permeability or provide a driving force for delivery. Although these systems successfully enhance delivery efficacy, they can also cause irritation, pain, and tissue damage. The third generation of drugs includes CPEs, biochemical enhancers, electroporation, cavitational ultrasound, microneedles, thermal ablation, and macromolecule delivery through tools, such as vaccines. The microneedle system is becoming more popular, and many approaches are currently being tested in clinical trials. 56 Microneedles have mainly focused on vaccine delivery, insulin delivery, or cosmetic applications because of their limitations for intracellular delivery. 21, 22 Biochemical enhancers, such as SPPs, which are composed of a few amino acids and can be conjugated to various cargo macromolecules, have recently been shown to be safe and effective enhancers for regulating skin cell behavior.
Various SPPs have been developed. These SPPs can be classified into 2 main groups: traditional CPPs (eg, TAT, oligoarginine, and PEP-1) and skin tissue-penetrating peptides (SPPs; eg, TD-1 and SPACE). [28] [29] [30] [31] [32] [33] Cyclopeptide TD-1 has been used to deliver insulin without covalent linkage to suppress serum glucose levels. 32 Cyclosporine A, FK506BP, and small interfering RNA have been delivered by using oligoarginine, PEP-1, or TAT to treat dermatitis in a mouse model. 28, 30, 31 However, several limitations were reported for these peptides. For instance, TD-1 transports cargo through the transfollicular route, which is less relevant for treating human subjects because hair follicles are rare on human skin. Moreover, oligoarginine was not efficiently delivered to viable epidermal and dermal cells without pyrenebutyrate, a hydrophobic counteranion; furthermore, SPACE peptide-conjugated cargo did not execute their proper functions in a disease model. 29, 32, 33 In our experiments the MTD-1067 and S3-2 peptides, which were screened by using phage display, were unable to deliver cargo protein into skin cells (see Fig E11 in this article's Online Repository for this article at www.jacionline. org). In addition, we found that TAT-rPTP and R9-rPTP did not prevent the development of dermatitis, and only AP-rPTP could suppress ear inflammation.
Although several previous studies have demonstrated successful transcutaneous drug delivery in animal models of skin disease, no clinically available topical therapeutics that use biochemical enhancers are available, posing possible limitations for their clinical use. 35 This limitation might be due to discrepancies between animal model skin and human skin. For instance, mouse skin, which is commonly used for cutaneous permeation studies and mice are common disease models, but mouse skin is significantly thinner than human skin. We found that AP-rPTP could modulate back skin inflammation, as well as ear skin inflammation, in CHS, AD-like, and psoriasis-like models. In addition, the application of 200 mg of AP-dTomato onto isolated human skin tissue samples showed successful intracellular localization in both the epidermis and dermis. This localization was rarely observed in the TAT-dTomato-treated samples, suggesting that AP-dTomato has a higher potential for clinical use than TAT. We also performed hair removal and tape stripping and showed that AP-dTomato was significantly delivered into the intact skin tissue, as demonstrated by the more even distribution in the dermis after tape stripping (see Fig E12, A, in this article's Online Repository for this article at www.jacionline.org). In dermatitis disease models AP-dTomato treatments without tape stripping resulted in more efficient delivery of AP-dTomato into the dermis of inflammatory tissue compared with control treatments (see Fig  E12, B) . Thus we suggest AP is a significantly improved thirdgeneration TDDS.
Intracellular protein delivery by AP involves lipid raftmediated endocytosis and macropinocytosis after heparan sulfate interaction, a mechanism similar to that of other CPPs. Phagocytic cells uptake CPP proteins better than lymphocytes, and activated or memory-like lymphocytes have better endocytosis ability than resting lymphocytes, suggesting heterogeneity of CPP-mediated protein delivery efficiency. 57, 58 Here we also consistently demonstrate CD11c 1 antigen-presenting cells or CD45 2 keratinocytes have higher intracellular AP-EGFP signal than CD3 1 cells. Interestingly, cysteine is a critical amino acid that contributes to the superior cellular uptake of APconjugated proteins. AP dimerization is mediated by its cysteine residue, thereby enhancing binding affinity to the cell membrane compared with the monomeric form of AP and providing entropy advantages. 59 The transfection efficacy of plasmid DNA has been shown to be enhanced by appending a C-terminal cysteine to penetratin and PenArg (a penetratin analog) and also to the EB1 sequence; this enhancement was mediated by dimerization. 59 CyLoP-1, a cysteine-rich peptide derived from the natural cationic polypeptide toxin crotamine, exhibited reduced delivery efficiency after its cysteine residue was substituted to a serine residue or deleted, 60 suggesting that cysteine enhances cellular penetration efficiency. We previously reported various human-derived CPPs, such as LPIN, 61 2IL-1a, 62 and dNP2. 36 Adding one cysteine to LPIN showed significantly increased protein delivery efficacy than seen with LPIN. dNP2 is a tandem repeat of NP2 sequence. 36 By adding a cysteine to NP2, it also exhibited significantly better delivery efficiency than NP2, suggesting cysteine is important for superior efficiency of AP. Tryptophan is commonly found in membrane surface proteins. The aromatic group of this amino acid creates noncovalent interactions with regions of p-electron density. 63, 64 Within basic charged amino acids, tryptophan induces glycosaminoglycan-dependent endocytosis through formation of the b-strand structure complex with glycosaminoglycans. 64 Therefore the tryptophan residue in AP also contributes to interactions with the cell membrane. This combination of functional amino acids in AP enhances intracellular drug delivery.
TC-PTP is a non-receptor-type protein tyrosine phosphatase encoded by the Ptpn2 gene that has been reported to negatively regulate cytokine and T-cell receptor (TCR) signaling. 47 Polymorphisms in TC-PTP have been widely reported in patients with various autoimmune diseases, but few studies have investigated the role of TC-PTP in patients with cutaneous inflammatory diseases. 65 However, spontaneous inflammation in the skin has been observed in CD4-specific TC-PTP knockout mice. 44 TC-PTP also regulates various cell-signaling pathways, including the Src family (involved in TCR signaling 47 ) and the JAK-STAT pathway (including its members JAK1, 43 ). Inflammatory cytokines that mainly use the JAK-STAT pathway induce inflammation and barrier impairment. 6 Various cytokines secreted from keratinocytes and T cells, including TSLP, IFN-g, IL-4, IL-5, Il-13, IL-22, IL-31, and IL-33, have a crucial role in AD pathogenesis. 6 Furthermore, TNF-a, IFN-g, IL-6, IL-22, and IL-17, which are secreted from keratinocytes, helper T cells, and gd T cells, are crucial in psoriasis pathogenesis, 15 with IL-17 playing a particularly important role. Cytokines are important initiators and regulators and are thus potential therapeutic targets. In previous reports mAbs that target cytokine signaling were shown to successfully treat skin inflammation. 18, 66 Dupilumab, which inhibits IL-4 and IL-13 dual signaling by targeting the IL-4 receptor a subunit, was also reported to have satisfactory efficacy and safety. 2 Moreover, an anti-p40 mAb ustekinumab, which blocks IL-12 and IL-23, received FDA approval for treating plaque psoriasis. 15 In addition to extracellular cytokine-targeting drugs, JAK-STAT inhibitors, such as tofacitinib, have also been developed under the assumption that targeting intracellular cytokine signaling is very attractive for a broad targeting approach. 67 We hypothesized that TC-PTP is an important target for regulating various inflammatory cytokine signals and that TCR signaling could also be targeted to regulate the complex inflammatory response in dermatitis. Topical tacrolimus therapy is the current clinical treatment and has been shown to significantly improve the severity of AD, without affecting serum IgE levels or peripheral blood leukocytes. 68 These findings were presumably due to blood concentrations of tacrolimus, which showed that the drug was rarely detected in most of the patients. 69 Oral cyclosporine therapy was used to treat the majority of patients with moderate-to-severe AD, some of whom had decreased serum IgE levels. 70 We found that transcutaneous AP-rPTP treatment resulted in slightly decreased serum IgE levels (see Fig E13 in this article's Online Repository for this article at www.jacionline.org), suggesting that further investigations should investigate the systemic administration effects of AP-rPTP. We also aim to investigate AP-rPTP in future clinical trials.
In summary, we demonstrate the technical feasibility of using a novel transdermal delivery peptide, AP, in a transcutaneous protein therapeutic developed to treat inflammatory skin diseases. This peptide-based macromolecular delivery method can potentially improve topical drug delivery of small molecules, proteins, and antibodies across the skin tissue barrier. Transcutaneous application of AP-rPTP by using the paper-patch technique could modulate cytokine signaling and TCR signaling in a substrate-specific manner, making this treatment strategy highly attractive for treating inflammatory skin diseases, such as AD and psoriasis.
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Key messages
d A novel transdermal delivery peptide consisting of only 9 amino acids, AP, exhibited potent efficacy for the intracellular delivery of macromolecules into mouse and human skin cells and tissues.
d A novel immunomodulatory recombinant protein, APrPTP, negatively regulates the JAK/STAT cytokine signaling pathway, T-cell activation, and T-cell proliferation on TCR stimulation.
d Transcutaneous administration of AP-rPTP alleviated tissue inflammation in both AD-like and psoriasis-like dermatitis mouse models, suggesting that AP-rPTP is a novel therapeutic biological drug candidate for human dermatitis.
